Nov. 16, 2026—Hologen and Sysmex Corp. have formed Saibogen, a blood intelligence company, as a joint venture. Saibogen will apply Hologen’s large medicine models to proprietary data generated by Sysmex hematology analyzers. The approach aims to unlock new insights from routine blood testing data, with no new instruments, reagents or samples, and create new clinical value for health care professionals and researchers.
“Saibogen’s ambition is to change what a hematology analyzer is for: from an instrument that reports a standard panel of parameters to a platform that delivers rich and dynamic biological insight without compromising accessibility,” according to a joint press release. The new company will deliver its blood intelligence products as software exclusively through Sysmex’s hematology analyzers.
“Every routine blood count measures tens of thousands of cells with remarkable precision, and much of that information goes unused,” Leila Luheshi, CEO of Saibogen, said. “We are building the AI to read it in full, so researchers, laboratories, and clinicians can learn far more from a test that is already part of everyday care.”
The company is based in Singapore. Its first offerings will be for research use only.